"Viking Therapeutics' Weight-Loss Drug Trial Yields Impressive Results, Stock Doubles"
TL;DR Summary
Viking Therapeutics' stock doubled after reporting positive results from a Phase 2 trial of its weight-loss drug VK2735, showing statistically significant reductions in body weight at all doses compared to placebo, with patients losing up to 14.7% of their body weight after 13 weeks. The treatment was well-tolerated, and the company plans to discuss next steps with the FDA. The news positions Viking as a potential competitor in the weight-loss drug market, and the company is also developing a treatment for NASH.
Topics:business#health-and-pharmaceuticals#obesity#phase-2-trial#viking-therapeutics#vk2735#weight-loss-drug
- Viking Therapeutics’ stock doubles after company reports positive results in trial of weight-loss drug MarketWatch
- Viking Therapeutics Stock Surges 100% on Positive Weight-Loss Drug Trial Barron's
- Obesity drug from Viking hits in trial, fueling competition in the field STAT
- Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results Investor's Business Daily
- Viking Therapeutic's (VKTX) Obesity Data Seen as 'Impressive' StreetInsider.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
85%
539 → 82 words
Want the full story? Read the original article
Read on MarketWatch